Publications
Breaking Alzheimer's: A 15 Year Crusade to Expose the Cause and Deliver the Cure
Dayan Goodenowe, PhD
(2021)
Brain ethanolamine phospholipids, neuropathology and cognition: A comparative post-mortem analysis of structurally specific plasmalogen and phosphatidyl species
Brain ethanolamine phospholipids, neuropathology and cognition: A comparative post-mortem analysis of structurally specific plasmalogen and phosphatidyl species (journal article)
Frontiers in Cell and Developmental Biology, volume 10 (2022).
Targeted Plasmalogen Supplementation: Effects on Blood Plasmalogens, Oxidative Stress Biomarkers, Cognition, and Mobility in Cognitively Impaired Persons
Targeted Plasmalogen Supplementation: Effects on Blood Plasmalogens, Oxidative Stress Biomarkers, Cognition, and Mobility in Cognitively Impaired Persons (journal article)
Frontiers in Cell and Developmental Biology, volume 10 (2022).
The effect of plasmalogen precursor supplementation on blood catalase and malondialdehyde levels in cognitively impaired persons
The effect of plasmalogen precursor supplementation on blood catalase and malondialdehyde levels in cognitively impaired persons (journal article)
Alzheimer's & Dementia, volume 17, issue S5 (2021).
The effect of plasmalogen precursor supplementation on blood plasmalogen and C‐reactive protein levels and cognition in cognitively impaired persons
The effect of plasmalogen precursor supplementation on blood plasmalogen and C‐reactive protein levels and cognition in cognitively impaired persons (journal article)
Alzheimer's & Dementia, volume 17, issue S6 (2021).
Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau
Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau (journal article)
Alzheimer's & Dementia, volume 16, issue 9, pages 1234-1247 (2020).
P1‐386: Association of Serum-Based Plasmalogens with Neuroimaging and Genetic Variation in Alzherimer’s Disease
P1‐386:Association of Serum-Based Plasmalogens with Neuroimaging and Genetic Variation in Alzherimer’s Disease (journal article)
Alzheimer's & Dementia, volume 15, issue 7S_Part_7 (2019).
Plasmalogen deficiency and neuropathology in Alzheimer's disease: Causation or coincidence?
Plasmalogen deficiency and neuropathology in Alzheimer's disease: Causation or coincidence? (journal article)
Alzheimer's & Dementia: Translational Research & Clinical Interventions, volume 5, issue 1, pages 524-532 (2019).
Serum Indices of Ethanolamine Plasmalogens and Phosphatide Metabolism in the Combined ADNI-1/GO/2 Cohort: Does the Liver Contribute to AD Risk by Failing to Supply Key Lipids to the Brain?
Alzheimer's & Dementia, volume 14, issue 7S_Part_18 (2018).
Serum Long-Chain N-3 Fatty Acid Levels Are Associated With Presynaptic Proteins in the Human Brain
[O3–11–04]: Serum Long-Chain N-3 Fatty Acid Levels Are Associated With Presynaptic Proteins in the Human Brain (journal article)
Alzheimer's & Dementia, volume 13, issue 7S_Part_19 (2017).
P4‐318: Apoe Genotype, Serum Plasmalogens, Cognition, and Mortality: a Pre‐Mortem Analysis in Elderly Persons
P4‐318: Apoe Genotype, Serum Plasmalogens, Cognition, and Mortality: a Pre‐Mortem Analysis in Elderly Persons (journal article)
Alzheimer's & Dementia, volume 12, issue 7S_Part_24 (2016).
P4‐319: Apoe Genotype, Serum Plasmalogens, Brain Amyloid and Tangles, and Cognition: a Pre‐/Post‐Mortem Analysis in Elderly Persons
P4‐319: Apoe Genotype, Serum Plasmalogens, Brain Amyloid and Tangles, and Cognition: a Pre‐/Post‐Mortem Analysis in Elderly Persons (journal article)
Alzheimer's & Dementia, volume 12, issue 7S_Part_24 (2016).
O2‐13‐05: The effects of ApoE genotype and serum plasmalogen metabotype on cognition and the odds of Alzheimer's disease in older persons
O2‐13‐05: The effects of ApoE genotype and serum plasmalogen metabotype on cognition and the odds of Alzheimer's disease in older persons (journal article)
Alzheimer's & Dementia, volume 11, issue 7S_Part_4 (2015).
P4‐225: Relation of plasmalogens, ApoE genotype, and Alzheimer's disease pathology to cognition: A post‐mortem analysis
P4‐225: Relation of plasmalogens, ApoE genotype, and Alzheimer's disease pathology to cognition: A post‐mortem analysis (journal article)
Alzheimer's & Dementia, volume 11, issue 7S_Part_19 (2015).
O4‐12‐06: The Alzheimer's metabolome: Identification of novel markers and treatment targets
O4‐12‐06: The Alzheimer's metabolome: Identification of novel markers and treatment targets (journal article)
Alzheimer's & Dementia, volume 11, issue 7S_Part_6 (2015).
P4‐224: Serum phosphatidylcholine changes in Alzheimer's disease and dementia are due to impaired peroxisomal beta oxidation
P4‐224: Serum phosphatidylcholine changes in Alzheimer's disease and dementia are due to impaired peroxisomal beta oxidation (journal article)
Alzheimer's & Dementia, volume 11, issue 7S_Part_19 (2015).
P4‐281: Relation of Plasmalogen Biosynthesis to Cognition and AD in Older Persons
Alzheimer's & Dementia, volume 10, issue 4S_Part_15 (2014).
Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease
Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease (journal article)
Lipids in Health and Disease, volume 10, issue 1, pages 227- (2011).
Circulating plasmalogen levels and Alzheimer Disease Assessment Scale–Cognitive scores in Alzheimer patients
Circulating plasmalogen levels and Alzheimer Disease Assessment Scale–Cognitive scores in Alzheimer patients (journal article)
Journal of Psychiatry and Neuroscience, volume 35, issue 1, pages 59-62 (2010).
Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia
Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia (journal article)
Journal of Lipid Research, volume 48, issue 11, pages 2485-2498 (2007).